234.54MMarket Cap-6507P/E (TTM)
9.560High8.330Low167.79KVolume9.180Open8.950Pre Close1.46MTurnover5.91%Turnover RatioLossP/E (Static)27.72MShares11.55052wk High2.18P/B24.02MFloat Cap2.34052wk Low--Dividend TTM2.84MShs Float29.690Historical High--Div YieldTTM13.74%Amplitude2.210Historical Low8.710Avg Price1Lot Size
Eliem Therapeutics Stock Forum
Onconova Tx merger w/ Trawsfynydd Tx
$Aditxt(ADTX.US)$ to acquire Appili Tx
TuHURA Biosciences merger w/ $Kintara Therapeutics(KTRA.US)$
$Johnson & Johnson(JNJ.US)$ to acquire $ShockWave Medical(SWAV.US)$
$Vertex Pharmaceuticals(VRTX.US)$ to acquire $Alpine Immune(ALPN.US)$
$Century Therapeutics(IPSC.US)$ to acquire Clade Tx
$Eliem Therapeutics(ELYM.US)$ to acquire Tenet Med.
$Incyte(INCY.US)$ to acquire Escient Pharm.
ONO Pharm to acquire $Deciphera Pharmaceuticals(DCPH.US)$
...
In an ambitious move that is set to redefine the landscape of the biopharmaceutical industry, Eliem Therapeutics, Inc. has officially announced its agreement to acquire Tenet Medicines, Inc. Alongside this acquisition, Eliem has also unveiled plans for a concurrent $120 million private placement, marking a significant financial investme...
📊⚡️📊
NEWS
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
Eliem Therapeutics, Inc. (ELYM) announces the acquisition of Tenet Medicines, Inc., focusing on advancing TNT119, an anti-CD19 antibody, for autoimmune diseases. The combined company expects to have $210 million in cash, including $120 million from a private placement. The acquisition aims to fund operations until 2027 and achieve key clinical miles...
No comment yet